This site is intended for healthcare professionals
CDK4/6 inhibitor selection in metastatic breast cancer

Expert opinion

Discover what our medical experts say on the clinical utility of CDK4/6 inhibitors (abemaciclib, ribociclib and palbociclib) for HR+/HER2- metastatic breast cancer, and the key considerations when selecting the right CDK4/6 inhibitor for your patient.

Medical expert interviews

Here, you can find the full medical expert interviews on CDK4/6 inhibitors for treating HR+/HER2- metastatic breast cancer with our breast cancer experts, Dr Gregory Vidal, Dr Laura Spring and Dr Alistair Ring. Whilst you may have spotted some of the clips related to the utility of, and differences between abemaciclib, ribociclib and palbociclib throughout the Learning Zone, there are more unanswered questions to discover in the full-length interview videos below.

Dr Gregory Vidal, MD, PhD

Dr Gregory Vidal, a medical oncologist at the West Cancer Center and Research Institute addresses some key questions on the use of CDK4/6 inhibitors for the treatment of HR+/HER2- metastatic breast cancer. Key discussion points include the safety and monitoring of abemaciclib, palbociclib and ribociclib in clinical practice and emerging investigational biomarkers of CDK4/6 resistance. He also discusses the importance of keeping up to date with the latest data for CDK4/6 inhibitors in treating breast cancer patients, as the field is ever-changing, with many new ongoing clinical trials in different patient settings.

Dr Gregory Vidal also helped to co-create an interactive eLearning module that further highlights the differences between the three CDK4/6 inhibitors; abemaciclib, palbociclib and ribociclib. The eLearning incorporates three patient cases for metastatic breast cancer, where one CDK4/6 inhibitor is better suited to each patient. The rationale for CDK4/6 inhibitor selection in each case is also discussed.

To go through the patient case studies, visit our eLearning module

Dr Laura Spring, MD

Dr Laura Spring from the Massachusetts General Hospital Cancer Center and Harvard Medical School tells us which factors influence her choice of CDK4/6 inhibitor for her patients. These include differences in both clinical and financial toxicity for the available inhibitors abemaciclib, palbociclib and ribociclib. She also highlights the need to understand resistance mechanisms, and cross-resistance between the three CDK4/6 inhibitors. Dr Spring also shares her excitement about the ongoing clinical trials for CDK4/6 inhibitors in the early breast cancer setting.

Dr Alistair Ring, MD, PhD

In this series of video clips, Dr Alistair Ring from The Royal Marsden in London talks about when he uses CDK4/6 inhibitors, both in general and in the context of endocrine resistant metastatic breast cancer. He also describes how he selects between the available CDK4/6 inhibitors, abemaciclib, palbociclib and ribociclib based on safety and patient comorbidities. He also points to the latest development in the utility of CDK4/6 inhibitors for metastatic breast cancer patients in the United Kingdom (UK).

Welcome:

Medical expert biographies

Dr Gregory Vidal, MD, PhD

Dr Gregory Vidal.jpgDr Gregory Vidal, MD, PhD, is a Medical Oncologist at West Cancer Center and Research Institute and Assistant Professor at the University of Tennessee Health Science Center. Dr Vidal trained as a clinical researcher at the University of Stanford, taking part in research led by leading medical researchers. The aim of his research then, and now, is to discover and develop safe and effective treatments for breast cancer. Dr Vidal is the recipient of multiple awards and he has authored and co-authored numerous research articles in journals including the New England Journal of Medicine, Lancet Oncology and Nature Communications.

Dr Laura Spring, MD

Dr Laura Spring.jpgDr Laura Spring, MD, is a Medical Oncologist and clinical researcher at the Massachusetts General Hospital Cancer Center and Harvard Medical School. Dr Spring is particularly interested in targeted therapies in the neoadjuvant setting and has conducted multiple breast cancer research trials for localised metastatic breast cancer. She has authored and co-authored multiple research and review articles in journals including Lancet, The Lancet Oncology and Clinical Cancer Research. Dr Spring is also the recipient of the Young Investigator Award from the ASCO Conquer Cancer Foundation for her work on blood-based testing in the neoadjuvant setting using circulating tumour cell (CTC) monitoring.

Dr Alistair Ring, MD, PhD

Dr Alistair Ring.jpgDr Alistair Ring, MD, PhD, is a Consultant Medical Oncologist at The Royal Marsden NHS Trust, and a principle investigator at the Institute of Cancer Research, London, UK. Dr Ring received his medical research degree at the Institute of Cancer in 2005 and his current research interests are in the management of early and metastatic breast cancer patients who are older. In 2018, he was appointed Honorary Reader in Breast Cancer Clinical Trials, at the Institute of Cancer Research. He has authored and co-authored many peer-reviewed research articles in journals such as The Lancet Oncology, Cancer Research and the European Journal of Cancer.

Welcome:
Welcome: